Abstract: A process for polymerization of vinyl chloride may include contacting vinyl chloride, demineralized water, at least one stabilizer agent, at least one dispersing agent, an initiator and optionally one or more comonomers; continuously feeding the vinyl chloride, demineralized water, at least one stabilizer agent, at least one dispersing agent, an initiator and optionally one or more comonomers into a tubular reactor having a length of at least 20 times an internal diameter of the tubular reactor; and continuously polymerizing the vinyl chloride, and optionally the one or more comonomers.

Abstract: Oxy-fuel combustion of a fuel stream, an oxygen stream and a recycle stream can form an exhaust stream, with, for example, a gas turbine. The exhaust stream can be separated into a water-rich stream and a carbon dioxide-rich stream. At least a portion of the carbon dioxide-rich stream can be divided to form the recycle stream. A second portion of the carbon dioxide-rich stream and a hydrogen stream can generate an exit stream, with, for example, a Sabatier reactor. The exit stream can be separated into a methane-rich gaseous product and a water-rich liquid product.

Abstract: The invention is directed to a water-soluble, environmentally-friendly, packaging wrap for the packaging of goods and parcels. The packaging wrap is formed by sealing together at least two sheets of water-soluble polymeric film to form unsealed areas within the wrap. After the goods or parcels are wrapped with the packaging material, air is then injected into the unsealed areas of the wrap to form air chambers to cushion the goods during transport.

Abstract: A curtain of a boom for harvesting brine shrimp eggs includes mesh sections for directing a flow of water in a first direction such that an amount of the brine shrimp eggs swept under the curtain of the boom during a harvesting process is minimized and a bottom section located below the mesh sections for directing a flow of water in a second direction during the harvesting process such that debris in the water is swept under the curtain of the boom.

Abstract: Transdermal diffusion cell testing vessel includes a container defining a chamber having an opening against which skin is placed, and a casing arranged partially around and spaced apart from part of the container to define a compartment therebetween. The chamber retains a saline solution and is not in flow communication with the compartment through which water is circulated. The vessel includes separate inlet ports and outlet ports, each including a conduit communicating with the chamber or compartment. The outlet port of the chamber is angled downward relative to a horizontal upper surface of the container against which skin being tested is placed. The vessel is used for conducting transdermal diffusion cell testing in combination with a solution source fluidly coupled to each vessel, a waste receptacle fluidly coupled to each vessel, a syringe pump fluidly coupled to a respective vessel, and a sample collector fluidly coupled to the syringe pump(s).

Abstract: Embodiments of the present invention feature methods and apparatus in which fluids circulating between a plurality of vessels containing different cell types or tissues are monitored for metabolites following the introduction of a sample.

Abstract: Transdermal diffusion cell testing vessel includes a container defining a chamber having an opening against which skin is placed, and a casing arranged partially around and spaced apart from part of the container to define a compartment therebetween. The chamber retains a saline solution and is not in flow communication with the compartment through which water is circulated. The vessel includes separate inlet ports and outlet ports, each including a conduit communicating with the chamber or compartment. The outlet port of the chamber is angled downward relative to a horizontal upper surface of the container against which skin being tested is placed. The vessel is used for conducting transdermal diffusion cell testing in combination with a solution source fluidly coupled to each vessel, a waste receptacle fluidly coupled to each vessel, a syringe pump fluidly coupled to a respective vessel, and a sample collector fluidly coupled to the syringe pump(s).

Abstract: Vessel for transdermal diffusion cell testing includes a container defining an interior chamber having an opening against which skin is placed, and a casing arranged partially around and spaced apart from part of the container to define a compartment therebetween. The chamber retains a saline solution and is not in flow communication with the compartment through which water is circulated. The vessel includes separate inlet ports and outlet ports, each including a conduit communicating with the chamber or compartment. The outlet port of the chamber is arranged above the inlet port of the chamber, proximate the opening of the chamber, and is angled downward relative to a horizontal upper surface of the container against which skin being tested is placed. Tilting of the vessel prior to or during introduction of solution prevents air bubbles from remaining between the skin and the solution.

Abstract: Pharmaceutical product release rate testing device includes a base, at least one carousel member rotatably mounted on the base, each carousel member including a plurality of test tube pockets each adapted to receive a test tube fillable with test media, and a dipping mechanism for dipping samples to be tested into the test tubes when present in the pockets and filled with test media. A rinsing/filling mechanism is provided to rinse or fill test tubes in one set of pockets while test tubes in another set of pockets are involved in the dipping process via the dipping mechanism. The carousel member is temperature-controlled such that all of the test tubes when present in the pockets are at substantially the same temperature for critical stages of the testing process. Methods for conducting pharmaceutical product release rate testing using the device are also disclosed.

Abstract: Pharmaceutical product release rate testing device includes a base, at least one carousel member rotatably mounted on the base, each carousel member including a plurality of test tube pockets each adapted to receive a test tube fillable with test media, and a dipping mechanism for dipping samples to be tested into the test tubes when present in the pockets and filled with test media. A rinsing/filling mechanism is provided to rinse or fill test tubes in one set of pockets while test tubes in another set of pockets are involved in the dipping process via the dipping mechanism. The carousel member is temperature-controlled such that all of the test tubes when present in the pockets are at substantially the same temperature for critical stages of the testing process. Methods for conducting pharmaceutical product release rate testing using the device are also disclosed.

Abstract: A method of rapidly analyzing unexpected metabolites in a metabolite analyzing system is disclosed. A control sample is run and analyzed to generate an exclusion list of unwanted sample components. A single analyte sample is then run and programmatically uses the exclusion list containing the unwanted metabolites to dynamically filter out data regarding components present in both the control sample and the analyte sample. The remaining components in the analyte sample are analyzed for unexpected metabolites of interest. The present invention allows for the analysis to be automated and eliminates the need for a second analyte sample run for the purpose of eliminating common components in the samples.

Abstract: Novel sulphones of Formula I are disclosed: wherein A completes a 4-7 membered ring optionally comprising up to two heteroatoms. The compounds modulate the action of ?-secretase and are therefore useful in the treatment or prevention of Alzheimer's disease.

Abstract: Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.

Abstract: Compounds of formula I: inhibit gamma-secretase and hence find use in treatment of Alzheimer's disease.

Abstract: Mass intensity values, isotopic ratios and exact mass differences between isotopes may be obtained and analyzed to determine if there are one or more masses of interest. In one implementation, a method will look among the mass intensity values for peaks of interest. The mass intensity values, representative of isotopic signatures, will be compared to a criteria in order to determine which of the masses are of interest. Although the invention is not so limited, examples of such criteria include mass intensity values above a specified threshold, within a certain ratio of another mass intensity value, and/or separation between the masses themselves. Optionally, a tolerance may be applied to the criteria. If masses are found to be of interest, MS/MS can automatically be triggered for one or all of the masses of interest, when an analyzing system such as an LC-MS-MS, GC-MS-MS or MALDI-MS-MS system is used.

Abstract: The present invention provides compounds of formula I: wherein R1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R3 is an alkyl, cycloalkyl, cycloalkylalkyl, amino or heterocyclyl group; R4 and R5 are hydrogen or alkyl or form a cycloalkyl ring; A is O or N; and m is zero or one; as inhibitors of GlyT1 and thus as useful for treating or preventing diseases such as schizophrenia; with the provision of pharmaceutical compositions, first and second medical uses and methods of treatment.

Abstract: The invention is drawn to a catalyst having a substantially bimodal support phase and an active metal phase that is suitable and stable for desulfurization of high-olefin content naphtha streams with minimal octane-loss running at low hydrogen pressure. The active metal phase preferably includes cobalt, molybdenum and at least one additional metal selected from the alkali-metals group.

Abstract: There is disclosed the treatment or prevention of diseases involving deposition of beta-amyloid in the brain, e.g. Alzheimer's disease, via the combined administration of a growth hormone secretagogue and a PDE4 inhibitor.

Abstract: Mass intensity values, isotopic ratios and exact mass differences between isotopes may be obtained and analyzed to determine if there are one or more masses of interest. In one implementation, a method will look among the mass intensity values for peaks of interest. The mass intensity values, representative of isotopic signatures, will be compared to a criteria in order to determine which of the masses are of interest. Although the invention is not so limited, examples of such criteria include mass intensity values above a specified threshold, within a certain ratio of another mass intensity value, and/or separation between the masses themselves. Optionally, a tolerance may be applied to the criteria. If masses are found to be of interest, MS/MS can automatically be triggered for one or all of the masses of interest, when an analyzing system such as an LC-MS-MS, GC-MS-MS or MALDI-MS-MS system is used.

Abstract: A method of programmatically reducing a set of collected LC-MS or LC-MS/MS data such that true chromatographic and MS peaks are identified for use in Metabonomics is disclosed. The identified peaks are used to create a list of LC/MS, GC/MS, DIOS-MS or MALDI-MS signals and responses for a batch of samples which appear in a Master Entity List. The samples in the Master Entity List are then subjected to isotope de-clustering and adduct removal prior to chemometrics being applied to automatically identify biomarkers. An LC-MS/MS or LC/MS, GC/MS, DIOS-MS or MALDI-MS acquisition list is generated for the signals identified as responsible for the PLS-DA or PCA separation. The LC or GC retention time, exact mass and MS/MS spectrum may be compared to databases of known compounds and identified compounds associated with biological parameters may be stored in a new compound database.